We propose renewal of the Specialized Program of Research Excellence (SPORE) in Breast Cancer at the UNC Lineberger Comprehensive Cancer Center for Years 10-14. One of four Breast Cancer SPOREs funded in 1992, the UNC SPORE?s unique goals emphasize multidisciplinary translational research that spans and links the population, clinical, and basic sciences, as well as emphasizing health disparities between African-American and Caucasian populations. The UNC Breast Cancer SPORE?s primary objectives are to: Population Science: Maintain and analyze two long-term, large, population-based studies (Carolina Breast Cancer Study; Long Island Breast Cancer Study) of invasive breast cancer and carcinoma in situ that have epidemiologic/risk data, tumor samples, blood, and germline DNA; use these studies to test hypotheses regarding breast cancer etiology, prognosis, progression, and response to therapy, as well as investigate disparities in incidence, mortality, and morbidity between African-American and Caucasian women. Clinical/Translational Science: Maintain an infrastructure for performing innovative, institutional breast cancer clinical trials providing human tissue endpoints for translational research projects; In specific projects: a) determine how to break self-tolerance to expressed antigens on breast cancer cells and use this information to clinical immunotherapeutic advantage; b) study breast cancer patients? genotype and somatic mutations and relate these to prognosis and response to therapy; c) analyze by cDNA micro array breast cancer gene expression before and after therapy to devise new markers of prognosis and response to therapy; and d) devise novel approaches to enhancing breast cancer chemotherapy efficacy based on knowledge of intracellular cell survival signaling and its inhibition; Core Facilities: Establish, maintain, and improve core facility technology to: (1) study somatic mutations in small human tumor samples; (2) perfect high-throughput genotyping of germline DNA; (3) analyze mRNA expression in cells and tumors using cDNA microarray; (4) validate new antibodies and FISH probes to analyze specific gene products in fresh and archival tumor samples; and (5) establish and maintain a data management, informatics, and analysis infrastructure. Development and Inter-SPORE Collaboration: Promote translational research projects through developmental pilot projects and recruit new investigators to breast cancer research; and Use our emphasis on population-based molecular epidemiology, minority health disparities, genomics and clinical research to enter into productive collaboration with other Breast Cancer SPOREs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058223-12S1
Application #
6950237
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Kuzmin, Igor A
Project Start
1992-09-30
Project End
2006-07-31
Budget Start
2004-08-18
Budget End
2005-07-31
Support Year
12
Fiscal Year
2004
Total Cost
$110,721
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820

Showing the most recent 10 out of 598 publications